Karen Colwill
Overview
Explore the profile of Karen Colwill including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
3437
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Colwill K, Galipeau Y, Stuible M, Gervais C, Arnold C, Rathod B, et al.
Clin Transl Immunology
. 2022 Mar;
11(3):e1380.
PMID: 35356067
Objectives: Antibody testing against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been instrumental in detecting previous exposures and analyzing vaccine-elicited immune responses. Here, we describe a scalable solution to...
32.
Tuite A, Fisman D, Abe K, Rathod B, Pasculescu A, Colwill K, et al.
Microbiol Spectr
. 2022 Feb;
10(1):e0256321.
PMID: 35196819
We have previously used composite reference standards and latent class analysis (LCA) to evaluate the performance of laboratory assays in the presence of tarnished gold standards. Here, we apply these...
33.
Tang X, Sharma A, Pasic M, Brown P, Colwill K, Gelband H, et al.
JAMA Netw Open
. 2022 Feb;
5(2):e2146798.
PMID: 35171263
Importance: The incidence of infection during SARS-CoV-2 viral waves, the factors associated with infection, and the durability of antibody responses to infection among Canadian adults remain undocumented. Objective: To assess...
34.
Drews S, Hu Q, Samson R, Abe K, Rathod B, Colwill K, et al.
Microbiol Spectr
. 2022 Feb;
10(1):e0226221.
PMID: 35171006
This study attempted to understand the levels of neutralizing titers and the breadth of antibody protection against wild-type and variant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Canadian blood...
35.
Yau K, Chan C, Abe K, Jiang Y, Atiquzzaman M, Mullin S, et al.
CMAJ
. 2022 Feb;
194(8):E297-E305.
PMID: 35115375
Background: Differences in immunogenicity between mRNA SARS-CoV-2 vaccines have not been well characterized in patients undergoing dialysis. We compared the serologic response in patients undergoing maintenance hemodialysis after vaccination against...
36.
Liu J, Budylowski P, Samson R, Griffin B, Babuadze G, Rathod B, et al.
Sci Adv
. 2022 Jan;
8(3):eabj9815.
PMID: 35044832
Safe and effective vaccines are needed to end the COVID-19 pandemic. Here, we report the preclinical development of a lipid nanoparticle–formulated SARS-CoV-2 mRNA vaccine, PTX-COVID19-B. PTX-COVID19-B was chosen among three...
37.
Sheffield W, Bhakta V, Howell A, Jenkins C, Serrano K, Johnson N, et al.
Transfusion
. 2021 Dec;
62(2):418-428.
PMID: 34907536
Background: Randomized clinical trial data show that early plasma transfusion may save lives among trauma patients. Supplying plasma in remote environments is logistically challenging. Freeze-dried plasma (FDP) offers a possible...
38.
Law J, Girard M, Chao G, Ward L, Isho B, Rathod B, et al.
J Immunol
. 2021 Dec;
208(2):429-443.
PMID: 34903642
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces T cell, B cell, and Ab responses that are detected for several months in recovered individuals. Whether this response resembles a typical...
39.
Drews S, Abe K, Hu Q, Samson R, Gingras A, Colwill K, et al.
Transfusion
. 2021 Oct;
62(1):37-43.
PMID: 34662434
Background: This pilot study assesses the ability of plasma collected from Canadian blood donors in the first wave of the SARS-CoV-2 pandemic to neutralize later SARS-CoV-2 variants of concern (VOCs)....
40.
Saeed S, OBrien S, Abe K, Yi Q, Rathod B, Wang J, et al.
PLoS One
. 2021 Sep;
16(9):e0257743.
PMID: 34555095
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence studies bridge the gap left from case detection, to estimate the true burden of the COVID-19 pandemic. While multiple anti-SARS-CoV-2 immunoassays...